Bai Ying, Bao Xueli, Mu Qianqian, Fang Xin, Zhu Ruyuan, Liu Chenyue, Mo Fangfang, Zhang Dongwei, Jiang Guangjian, Li Ping, Gao Sihua, Zhao Dandan
College of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, China.
PeerJ. 2021 Feb 3;9:e10598. doi: 10.7717/peerj.10598. eCollection 2021.
To observe the effect of ginsenoside Rb1, salvianolic acid B and their combination on glucolipid metabolism and structural changes of gut microbiota.
Eight-week-old C57BL/6J mice were fed 45% high-fat diet to induce obesity. The obese mice were randomly divided into four groups, Con group as model control, ginsenoside Rb1 (Rb1) group, salvianolic acid B (SalB) group and ginsenoside Rb1+ salvianolic acid B (Rb1SalB) group. Mice in Rb1, SalB and Rb1SalB group were treated by gavage with ginsenoside Rb1, salvianolic acid B and the combination of the two ingredients, respectively. While mice in Con group were given the same amount of sterile water. The intervention lasted 8 weeks. Body weight and fasting blood glucose were measured every 2 weeks. Oral glucose tolerance test was conducted on the 4th and 8th week of drug intervention. At the end of the experiment, total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol and non-esterified fatty acid content as well as glycated hemoglobin were measured and feces were collected for 16S rDNA sequencing.
Both ginsenoside Rb1 and Rb1SalB combination decreased body weight significantly ( < 0.05). Ginsenoside Rb1, salvianolic acid B and their combination alleviated fasting blood glucose, glycated hemoglobin and blood lipid profiles effectively ( < 0.05, compared with the corresponding indicators in Con group). Oral glucose tolerance test results at the 8th week showed that glucose tolerance was significantly improved in all three treatment groups. Ginsenoside Rb1, salvianolic acid B and their combination reduced the overall diversity of gut microbiota in feces and changed the microbial composition of the obese mice. LDA effect size (LefSe) analysis revealed the key indicator taxa corresponding to the treatment.
Ginsenoside Rb1, salvianolic acid B and their combination could lower blood glucose and lipid level, and improve glucose tolerance of obese mice. The above effect may be at least partially through modulation of gut microbial composition.
观察人参皂苷Rb1、丹酚酸B及其组合对糖脂代谢及肠道微生物群结构变化的影响。
将8周龄C57BL/6J小鼠喂食45%高脂饮食以诱导肥胖。将肥胖小鼠随机分为四组,Con组作为模型对照,人参皂苷Rb1(Rb1)组、丹酚酸B(SalB)组和人参皂苷Rb1+丹酚酸B(Rb1SalB)组。Rb1组、SalB组和Rb1SalB组小鼠分别通过灌胃给予人参皂苷Rb1、丹酚酸B及两种成分的组合。而Con组小鼠给予等量无菌水。干预持续8周。每2周测量体重和空腹血糖。在药物干预的第4周和第8周进行口服葡萄糖耐量试验。实验结束时,测量总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和非酯化脂肪酸含量以及糖化血红蛋白,并收集粪便进行16S rDNA测序。
人参皂苷Rb1和Rb1SalB组合均显著降低体重(P<0.05)。人参皂苷Rb1、丹酚酸B及其组合有效缓解了空腹血糖、糖化血红蛋白和血脂水平(与Con组相应指标相比,P<0.05)。第8周的口服葡萄糖耐量试验结果表明,所有三个治疗组的葡萄糖耐量均显著改善。人参皂苷Rb1、丹酚酸B及其组合降低了粪便中肠道微生物群的总体多样性,并改变了肥胖小鼠的微生物组成。线性判别分析效应大小(LefSe)分析揭示了与治疗相对应的关键指示分类群。
人参皂苷Rb1、丹酚酸B及其组合可降低肥胖小鼠的血糖和血脂水平,并改善葡萄糖耐量。上述作用可能至少部分是通过调节肠道微生物组成实现的。